These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3046689)

  • 1. Correlation between low CSA plasma concentration and severity of acute GvHD in bone marrow transplantation.
    Schmidt H; Ehninger G; Dopfer R; Blaurock M; Naumann R; Einsele H; Haen M; Schüch K; Jaschonek K; Niethammer D
    Blut; 1988 Sep; 57(3):139-42. PubMed ID: 3046689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Six weeks of continuous intravenous cyclosporine and short-course methotrexate as prophylaxis for acute graft-versus-host disease after allogeneic bone marrow transplantation.
    Beelen DW; Quabeck K; Kaiser B; Wiefelspütz J; Scheulen ME; Graeven U; Grosse-Wilde H; Sayer HG; Schaefer UW
    Transplantation; 1990 Sep; 50(3):421-7. PubMed ID: 2402791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ciclosporin A: correlation of blood levels with acute graft-versus-host disease after bone marrow transplantation.
    Bandini G; Strocchi E; Ricci P; Rizzi S; Boschi S; Guardigli C; Calori E; Motta MR; Giudice V; Rosti G
    Acta Haematol; 1987; 78(1):6-12. PubMed ID: 3116813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of cyclosporine dosage and plasma levels in efficacy and toxicity in bone marrow transplant recipients.
    Lindholm A; Ringdén O; Lönnqvist B
    Transplantation; 1987 May; 43(5):680-4. PubMed ID: 3554661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclosporine and methylprednisolone after allogeneic marrow transplantation: association between low cyclosporine concentration and risk of acute graft-versus-host disease.
    Przepiorka D; Shapiro S; Schwinghammer TL; Bloom EJ; Rosenfeld CS; Shadduck RK; Venkataramanan R
    Bone Marrow Transplant; 1991 Jun; 7(6):461-5. PubMed ID: 1873593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclosporine in human bone marrow transplantation. Serum concentration, graft-versus-host disease, and nephrotoxicity.
    Gratwohl A; Speck B; Wenk M; Forster I; Müller M; Osterwalder B; Nissen C; Follath F
    Transplantation; 1983 Jul; 36(1):40-4. PubMed ID: 6346614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial comparing use of cyclosporin and methotrexate for graft-versus-host disease prophylaxis in bone marrow transplant recipients with haematological malignancies.
    Ringdén O; Bäckman L; Lönnqvist B; Heimdahl A; Lindholm A; Bolme P; Gahrton G
    Bone Marrow Transplant; 1986 May; 1(1):41-51. PubMed ID: 3332119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclosporin A serum and blood levels in marrow graft recipients: correlation with administered dose, serum creatinine and graft-versus-host disease.
    Bacigalupo A; Di Giorgio F; Frassoni F; Van Lint MT; Raffo MR; Gogioso L; Viale M; Marmont AM
    Acta Haematol; 1984; 72(3):155-62. PubMed ID: 6438979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [CD25 monoclonal antibody for GVHD prophylaxis in non-T-cell depleted haploidentical bone marrow transplantation for treatment of childhood leukemia].
    Chen HR; Ji SQ; Yan HM; Wang HX; Liu J; Xue M; Zhu L
    Zhonghua Er Ke Za Zhi; 2004 Apr; 42(4):294-8. PubMed ID: 15157394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose cyclosporine and corticosteroids for prophylaxis of acute and chronic graft-versus-host disease.
    Schwinghammer TL; Bloom EJ; Rosenfeld CS; Wilson JW; Przepiorka D; Shadduck RK
    Bone Marrow Transplant; 1995 Jul; 16(1):147-54. PubMed ID: 7581115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
    Aschan J; Ringdén O
    Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microangiopathy following allogeneic marrow transplantation. Association with cyclosporine and methylprednisolone for graft-versus-host disease prophylaxis.
    Kalhs P; Brugger S; Schwarzinger I; Greinix HT; Keil F; Kyrle PA; Knöbl P; Schneider B; Höcker P; Linkesch W
    Transplantation; 1995 Nov; 60(9):949-57. PubMed ID: 7491699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cyclosporine as prophylaxis for graft versus host disease in adults undergoing allogeneic bone marrow transplantation].
    Matsushita T; Akatsuka Y; Towatari M; Takeyama K; Miyamura K; Sugihara T; Minami S; Kodera Y
    Rinsho Ketsueki; 1989 Apr; 30(4):429-36. PubMed ID: 2671437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methotrexate combined with cyclosporin A decreases graft-versus-host disease, but increases leukemic relapse compared to monotherapy.
    Aschan J; Ringdén O; Sundberg B; Gahrton G; Ljungman P; Winiarski J
    Bone Marrow Transplant; 1991 Feb; 7(2):113-9. PubMed ID: 2049554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of tacrolimus, methotrexate, and methylprednisolone prevents acute but not chronic graft-versus-host disease in unrelated bone marrow transplantation.
    Ogawa H; Soma T; Hosen N; Tatekawa T; Tsuboi A; Oji Y; Tamaki H; Kawakami M; Ikegame K; Murakami M; Fujioka T; Kim EH; Oka Y; Sugiyama H
    Transplantation; 2002 Jul; 74(2):236-43. PubMed ID: 12151737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot study of low-dose cyclosporin for graft-versus-host prophylaxis in marrow transplantation.
    Stockschlaeder M; Storb R; Pepe M; Longton G; McDonald G; Anasetti C; Appelbaum F; Doney K; Martin P; Sullivan K
    Br J Haematol; 1992 Jan; 80(1):49-54. PubMed ID: 1536809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylaxis for acute graft-versus-host disease following unrelated donor bone marrow transplantation.
    Phillips GL; Nevill TJ; Spinelli JJ; Nantel SH; Klingemann HG; Barnett MJ; Shepherd JD; Chan KW; Meharchand JM; Sutherland HJ
    Bone Marrow Transplant; 1995 Feb; 15(2):213-9. PubMed ID: 7539667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective trial of mycophenolate mofetil-cyclosporine A prophylaxis for acute GVHD after G-CSF stimulated allogeneic bone marrow transplantation with HLA-identical sibling donors in patients with severe aplastic anemia and hematological malignancies.
    Ostronoff F; Ostronoff M; Souto-Maior AP; Domingues M; Sucupira A; Manso DA; de Lima AK; Monteiro PG; Florêncio R; Calixto R
    Clin Transplant; 2009; 23(1):33-8. PubMed ID: 18727660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylaxis of graft-versus-host disease in identical sibling donor bone marrow transplant by anti-IL-2 receptor monoclonal antibody LO-Tact-1.
    Ferrant A; Latinne D; Bazin H; Straetmans N; Cornet A; de la Parra B; Michaux JL
    Bone Marrow Transplant; 1995 Oct; 16(4):577-81. PubMed ID: 8528175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.